One advantage of sparsentan over other medications for IgA nephropathy is that it does not suppress your immune system, lowering your risk for infections. Iptacopan acts on a specific process in ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...

Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US ...

Multiple medications are now available to treat IgA nephropathy, including budesonide (Tarpeyo), sparsentan (Filspari), and iptacopan (Fabhalta). But Miller’s treatment options were more limited ...

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

The late-breaking oral presentation will feature new analyses from the Phase 3 DUPLEX Study of FILSPARI® (sparsentan ... as a foundational therapy in IgA nephropathy (IgAN).

Edgar Lerma, MD, provides insights into the pathophysiology of IgA nephropathy (IgAN) and the therapeutic promise of ...

“Since its approval in IgA nephropathy, we have seen the positive impact FILSPARI ... the study were published in the New England Journal of Medicine and showed that sparsentan delivered clinically ...

IgA nephropathy (IgAN), also called Berger's ... Concomitant use with a strong CYP3A inhibitor increases sparsentan exposure which may increase the risk of FILSPARI adverse reactions.